COVID-19合并或繼發細菌感染的診治研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

李健權 ¹ , 韓婧 ² , 林鑫 ³ , 張謙 ⁴ , 周厚榮 ⁵ ,  張湘燕 ²

1. ;
2. ;
3. ;
4. ;
5. ;

Corresponding?author：

張湘燕, Email: zxy35762@126.com

Keywords：

DOI：

10.7507/1671-6205.202206040

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李健權, 韓婧, 林鑫, 張謙, 周厚榮, 張湘燕. COVID-19合并或繼發細菌感染的診治研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2023, 22(8): 596-599. doi: 10.7507/1671-6205.202206040 Copy

1.	Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J, 2021, 23(1): 14.
2.	Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis, 2008, 198(7): 962-970.
3.	Martin Loeches I, Corral AS, Diaz E, et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A (H1N1) virus. Chest, 2011, 139(3): 555-562.
4.	Rice TW, Lewis R, Timothy MU, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med, 2012, 40(5): 1487-1498.
5.	Mutair, A, Ambani Z, Narrative review of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: updates and implications for practice. J Int Med Res, 2020, 48(1): 30-58.
6.	Nassar MS, Bakhrebah MA, Meo SA, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci, 2018, 22(15): 4956-4961.
7.	Musuuza J, Watson L, Parmasad V, et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS One, 2021, 16(5): e0251170.
8.	Westblade LF, Simon MS, Satlin M J. Bacterial coinfections in coronavirus disease 2019. Trends Microbiol, 2021, 29(10): 930-941.
9.	Karami Z, Bram T, Anton SM. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (Lond), 2021, 53(2): 102-110.
10.	Vaughn, VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis, 2021, 72(10): e533-e541.
11.	Elabbadi A, Matthieu T, Grigoris T, et al. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia. Infection, 2021, 49(3): 559-562.
12.	Kolenda C, Ranc AG, Boisset S, et al. Assessment of respiratory bacterial coinfections among severe acute respiratory syndrome coronavirus 2-positive patients hospitalized in intensive care units using conventional culture and BioFire, FilmArray Pneumonia Panel plus assay. Open Forum Infect Dis, 2020, 7(11): ofaa484.
13.	Contou, D, Claudinon A, Pajot O, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care, 2020, 10(1): 119-125.
14.	胡明, 李緒言, 邱海波, 等. 新型冠狀病毒肺炎患者繼發細菌感染防治的體會與建議. 中華重癥醫學電子雜志, 2020, 6(2): 230-232.
15.	Huang L, Wang Y, Wang L, et al. Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: a case report. Medicine (Baltimore), 2020, 99(27): e20956.
16.	Luo Y, Xie YL, Zhang WJ, et al. Combination of lymphocyte number and function in evaluating host immunity. Aging (Albany NY), 2019, 11(24): 12685-12707.
17.	Naveen KV, Saravanakumar K, Sathiyaseelan A, et al. Human fungal infection, immune response, and clinical challenge - a perspective during COVID-19 pandemic. Appl Biochem Biotechnol, 2022, 10(7): 151-178.
18.	賴展翔, 范穎敏, 歐靜怡, 等. 新型冠狀病毒肺炎合并細菌及真菌感染的診療特點. 實用醫學雜志, 2021, 37(1): 16-19.
19.	Singulani JL, Danielle LS, Caroline ML, et al. The impact of COVID-19 on antimicrobial prescription and drug resistance in fungi and bacteria. Braz J Microbiol, 2022, 53(4): 1925-1935.
20.	Seitz T, Holbik J, Grieb A, et al. The role of bacterial and fungal superinfection in critical COVID-19. Viruses, 2022, 14(12): 2785.
21.	王蓉, 謝伶俐, 杜鵬, 等. 新型冠狀病毒肺炎96例臨床分析. 中國呼吸與危重監護雜志, 2020, 19(2): 144-147.
22.	Wang L, Amin AK, Priya K, et al. An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. J Antimicrob Chemother, 2021, 76(3): 796-803.
23.	Nasir N, Rehman FU, Omair SF. Risk factors for bacterial infections in patients with moderate to severe COVID-19: a case-control study. J Med Virol, 2021, 93(7): 4564-4569.
24.	Patton MJ, Orihuela CJ, Harrod KS, et al. COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. Crit Care, 2023, 27(1): 34-45.
25.	Schons MJ, Caliebe A, Spinner CD, et al. All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort. Infection, 2022, 50(2): 423-436.
26.	Abdela SG, Liesenborghs L, Tadese F, et al. Antibiotic overuse for COVID-19: are we adding insult to injury? Am J Trop Med Hyg, 2021, 105(6): 1519-1520.
27.	Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect, 2021, 27(4): 520-531.
28.	Gao CA, Pickens CI, Nebreda LM, et al. Clinical features of COVID-19 and differentiation from other causes of CAP. Semin Respir Crit Care Med, 2023, 44(1): 8-20.
29.	黃秋芬, 曾惠清, 王洺輝等. 新型冠狀病毒肺炎嚴重程度相關生物學預測因子的研究進展. 中國呼吸與危重監護雜志, 2022, 21(1): 71-75.
30.	Heer RS, Mandal AJ, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. Ann Clin Biochem, 2021, 58(5): 520-527.
31.	Peng XH, Cruz CSD, Sharma L. Coronaviruses, lysosomes, and secondary bacterial infections: coronaviruses outsmart the host. DNA Cell Biol, 2023, 42(4): 189-193.
32.	Pettit NN, Nguyen TC, Alison KL, et al. Reducing the use of empiric antibiotic therapy in COVID-19 on hospital admission. BMC Infect Dis, 2021, 21(1): 516-529.
33.	Puzniak L, Bauer KA, Kalvin C, et al. Effect of inadequate empiric antibacterial therapy on hospital outcomes in SARS-CoV-2-positive and -negative US patients with a positive bacterial culture: a multicenter evaluation from march to november 2020. Open Forum Infect Dis, 2021, 8(6): 232-248.
34.	Sieswerda E, Mark GJ, Bonten MJ, et al. Recommendations for Antibacterial Therapy in Adults with COVID-19 - An Evidence Based Guideline. Clin Microbiol Infect, 2021, 27(1): 61-66.
35.	Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med, 2021, 47(11): 1181-1247.
36.	World Health Organization. Coronavirus disease (COVID-19) technical guidance.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance2021.
37.	Calderon M, Grace G, Sarah W, et al. , Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis, 2023, 23(1): 14-29.

1. Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J, 2021, 23(1): 14.
2. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis, 2008, 198(7): 962-970.
3. Martin Loeches I, Corral AS, Diaz E, et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A (H1N1) virus. Chest, 2011, 139(3): 555-562.
4. Rice TW, Lewis R, Timothy MU, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med, 2012, 40(5): 1487-1498.
5. Mutair, A, Ambani Z, Narrative review of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: updates and implications for practice. J Int Med Res, 2020, 48(1): 30-58.
6. Nassar MS, Bakhrebah MA, Meo SA, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci, 2018, 22(15): 4956-4961.
7. Musuuza J, Watson L, Parmasad V, et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS One, 2021, 16(5): e0251170.
8. Westblade LF, Simon MS, Satlin M J. Bacterial coinfections in coronavirus disease 2019. Trends Microbiol, 2021, 29(10): 930-941.
9. Karami Z, Bram T, Anton SM. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (Lond), 2021, 53(2): 102-110.
10. Vaughn, VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis, 2021, 72(10): e533-e541.
11. Elabbadi A, Matthieu T, Grigoris T, et al. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia. Infection, 2021, 49(3): 559-562.
12. Kolenda C, Ranc AG, Boisset S, et al. Assessment of respiratory bacterial coinfections among severe acute respiratory syndrome coronavirus 2-positive patients hospitalized in intensive care units using conventional culture and BioFire, FilmArray Pneumonia Panel plus assay. Open Forum Infect Dis, 2020, 7(11): ofaa484.
13. Contou, D, Claudinon A, Pajot O, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care, 2020, 10(1): 119-125.
14. 胡明, 李緒言, 邱海波, 等. 新型冠狀病毒肺炎患者繼發細菌感染防治的體會與建議. 中華重癥醫學電子雜志, 2020, 6(2): 230-232.
15. Huang L, Wang Y, Wang L, et al. Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: a case report. Medicine (Baltimore), 2020, 99(27): e20956.
16. Luo Y, Xie YL, Zhang WJ, et al. Combination of lymphocyte number and function in evaluating host immunity. Aging (Albany NY), 2019, 11(24): 12685-12707.
17. Naveen KV, Saravanakumar K, Sathiyaseelan A, et al. Human fungal infection, immune response, and clinical challenge - a perspective during COVID-19 pandemic. Appl Biochem Biotechnol, 2022, 10(7): 151-178.
18. 賴展翔, 范穎敏, 歐靜怡, 等. 新型冠狀病毒肺炎合并細菌及真菌感染的診療特點. 實用醫學雜志, 2021, 37(1): 16-19.
19. Singulani JL, Danielle LS, Caroline ML, et al. The impact of COVID-19 on antimicrobial prescription and drug resistance in fungi and bacteria. Braz J Microbiol, 2022, 53(4): 1925-1935.
20. Seitz T, Holbik J, Grieb A, et al. The role of bacterial and fungal superinfection in critical COVID-19. Viruses, 2022, 14(12): 2785.
21. 王蓉, 謝伶俐, 杜鵬, 等. 新型冠狀病毒肺炎96例臨床分析. 中國呼吸與危重監護雜志, 2020, 19(2): 144-147.
22. Wang L, Amin AK, Priya K, et al. An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. J Antimicrob Chemother, 2021, 76(3): 796-803.
23. Nasir N, Rehman FU, Omair SF. Risk factors for bacterial infections in patients with moderate to severe COVID-19: a case-control study. J Med Virol, 2021, 93(7): 4564-4569.
24. Patton MJ, Orihuela CJ, Harrod KS, et al. COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. Crit Care, 2023, 27(1): 34-45.
25. Schons MJ, Caliebe A, Spinner CD, et al. All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort. Infection, 2022, 50(2): 423-436.
26. Abdela SG, Liesenborghs L, Tadese F, et al. Antibiotic overuse for COVID-19: are we adding insult to injury? Am J Trop Med Hyg, 2021, 105(6): 1519-1520.
27. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect, 2021, 27(4): 520-531.
28. Gao CA, Pickens CI, Nebreda LM, et al. Clinical features of COVID-19 and differentiation from other causes of CAP. Semin Respir Crit Care Med, 2023, 44(1): 8-20.
29. 黃秋芬, 曾惠清, 王洺輝等. 新型冠狀病毒肺炎嚴重程度相關生物學預測因子的研究進展. 中國呼吸與危重監護雜志, 2022, 21(1): 71-75.
30. Heer RS, Mandal AJ, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. Ann Clin Biochem, 2021, 58(5): 520-527.
31. Peng XH, Cruz CSD, Sharma L. Coronaviruses, lysosomes, and secondary bacterial infections: coronaviruses outsmart the host. DNA Cell Biol, 2023, 42(4): 189-193.
32. Pettit NN, Nguyen TC, Alison KL, et al. Reducing the use of empiric antibiotic therapy in COVID-19 on hospital admission. BMC Infect Dis, 2021, 21(1): 516-529.
33. Puzniak L, Bauer KA, Kalvin C, et al. Effect of inadequate empiric antibacterial therapy on hospital outcomes in SARS-CoV-2-positive and -negative US patients with a positive bacterial culture: a multicenter evaluation from march to november 2020. Open Forum Infect Dis, 2021, 8(6): 232-248.
34. Sieswerda E, Mark GJ, Bonten MJ, et al. Recommendations for Antibacterial Therapy in Adults with COVID-19 - An Evidence Based Guideline. Clin Microbiol Infect, 2021, 27(1): 61-66.
35. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med, 2021, 47(11): 1181-1247.
36. World Health Organization. Coronavirus disease (COVID-19) technical guidance.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance2021.
37. Calderon M, Grace G, Sarah W, et al. , Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis, 2023, 23(1): 14-29.

Previous Article
PD-1/PD-L1通路在哮喘發病機制中的研究進展
Next Article
淋巴管平滑肌瘤病治療的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

COVID-19合并或繼發細菌感染的診治研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content